Evaluation of Myocardial Viability : Dual Energy Cardiac CT vs. Cardiac MRI

NCT ID: NCT02360150

Last Updated: 2016-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is therefore to show that associated with cardiac angiography echocardiography, in myocardial seen late, would provide the information necessary for the decision revascularization, in a timely manner.

This would allow the patient to avoid duplication of tests including risk related to coronary angiography (bleeding complications, stroke ...) and those related to the implantation of coronary stent (stent) without expected earnings in case of non-viability . This would also reduce the length of hospital stay and costs due to numerous reviews.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous coronary intervention is not recommended in stable patients with late presentation myocardial infarction, and myocardial viability needs to be evaluated before the procedure. The aim of the study is to evaluate the sensibility and specificity of dual-energy CT for the evaluation of myocardial viability in comparison to cardiac MRI.

The experimental procedure is limited to a second CT acquisition performed 10 minutes in dual energy mode.

Sensitivity and Specificity of delayed enhancement \>50% of myocardial thickness provided by dual-energy CT will be evaluated in comparison to cardiac MRI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

second propeller arm scanner

The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.

Group Type EXPERIMENTAL

second propeller arm scanner

Intervention Type RADIATION

The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

second propeller arm scanner

The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman
* Major patient
* Patient with electrical, biological and clinical signs of myocardial infarction, with late presentation (\>24 hours)
* Creatinine clearance (calculated using the Cockcroft (\<age 65) or MDRD (\> 65 years))formula \> 30 ml / min.
* Affiliation to the french social security scheme.
* Women of childbearing age: Negative pregnancy test (urine test).
* Postmenopausal women, menopause confirmation of diagnosis
* Patient able to understand the spoken and written French.
* Signature of informed consent

Exclusion Criteria

* Collapsus or organ failure requiring urgent care in intensive care unit
* Arrhythmia and/or non-reducible tachycardia.
* History of allergic reaction after iodinated contrast medium injection.
* History of nephrogenic systemic fibrosis.
* History of claustrophobia
* Unbalanced asthma.
* Acute pulmonary edema.
* Pregnant or breastfeeding women.
* Clinical signs of thyrotoxicosis.
* Person placed under judicial protection,
* Patient suffering from serious psychiatric disease.
* Patients participating in another clinical trial.
* Contraindication to MRI
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Rouen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin DUBOURG, Doctor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Rouen

Jean-Nicolas DACHER, Professor

Role: STUDY_DIRECTOR

University Hospital, Rouen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Rouen

Rouen, Normandy, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Benjamin DUBOURG, Doctor

Role: CONTACT

2 32 88 64 96 ext. +33

Jérome CAUDRON, Doctor

Role: CONTACT

2 32 88 64 96 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Benjamin DUBOURG, Doctor

Role: primary

2 32 88 64 96 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013/205/HP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dobutamine vs Adenosine CMR Study
NCT03661827 COMPLETED NA